Volume 77, Issue 1 pp. 31-35
Original Article
Free Access

Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma

Marin Nola

Marin Nola

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska

Search for more papers by this author
Steven Z. Pavletic

Corresponding Author

Steven Z. Pavletic

Department of Internal Medicine-Section of Oncology/Hematology, University of Nebraska Medical Center, Omaha, Nebraska

National Cancer Institute, Building 10, Room 12S241, 10 Center Drive, Bethesda, MD 20892-1907Search for more papers by this author
Dennis D. Weisenburger

Dennis D. Weisenburger

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska

Search for more papers by this author
Lynette M. Smith

Lynette M. Smith

Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, Nebraska

Search for more papers by this author
Martin A. Bast

Martin A. Bast

Department of Internal Medicine-Section of Oncology/Hematology, University of Nebraska Medical Center, Omaha, Nebraska

Search for more papers by this author
Julie M. Vose

Julie M. Vose

Department of Internal Medicine-Section of Oncology/Hematology, University of Nebraska Medical Center, Omaha, Nebraska

Search for more papers by this author
James O. Armitage

James O. Armitage

Department of Internal Medicine-Section of Oncology/Hematology, University of Nebraska Medical Center, Omaha, Nebraska

Search for more papers by this author
First published: 11 August 2004
Citations: 13

Abstract

The term “B-cell small lymphocytic lymphoma” (B-SLL) is generally reserved for patients with lymph node masses that show the histology and immunophenotype of B-cell chronic lymphocytic leukemia (B-CLL) but who are not leukemic. The aim of our study was to define clinical factors that predict for survival in B-SLL. Thirty-nine patients with B-SLL and with less than 5,000 mature-appearing lymphocytes/μL in the peripheral blood were studied. The median follow-up of survivors was 6.6 years (range, 1.6–12.3 years). The estimated 5-year overall survival (OS) and failure-free survival (FFS) were 66% and 23%, respectively. In the univariate analysis, significant adverse predictors for OS were age ≥60 years, B symptoms, elevated serum LDH, low hemoglobin (<11 g/dL), and high International Prognostic Index (IPI) score (3–5). In multivariate analysis, the IPI score was the only significant predictor of OS. Anemia and B symptoms were additionally predictive of poor OS in patients with low IPI scores. Am. J. Hematol. 77:31–35, 2004. © 2004 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.